{"id":11905,"date":"2023-06-07T05:08:14","date_gmt":"2023-06-07T03:08:14","guid":{"rendered":"https:\/\/ggba.swiss\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/"},"modified":"2023-07-04T13:44:20","modified_gmt":"2023-07-04T11:44:20","slug":"lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/","title":{"rendered":"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux"},"content":{"rendered":"\n

Les traitements contre le cancer, comme les traitements contre le diab\u00e8te, l’ob\u00e9sit\u00e9 ou les maladies cardiovasculaires, sont un \u00ab\u00a0Saint Graal\u00a0\u00bb pour l’industrie pharmaceutique. Lonza investit massivement dans les conjugu\u00e9s anticorps-m\u00e9dicament (ADCs), qui sont des traitements innovants et prometteurs capables de d\u00e9livrer pr\u00e9cis\u00e9ment des mol\u00e9cules hautement toxiques directement aux tumeurs.<\/p>\n

Les ADCs combinent un anticorps avec une \u00ab\u00a0charge utile\u00a0\u00bb, souvent une mol\u00e9cule cytotoxique (qui tue les cellules). \u00ab\u00a0Ce sont des traitements extr\u00eamement innovants et prometteurs parce qu’ils parviennent \u00e0 transporter une mol\u00e9cule hautement toxique et \u00e0 la d\u00e9livrer pr\u00e9cis\u00e9ment \u00e0 la tumeur\u00a0\u00bb, a expliqu\u00e9 le professeur Olivier Michielin, chef du d\u00e9partement d’oncologie des HUG<\/a> et du service d’oncologie de pr\u00e9cision<\/a>.<\/p>\n

L’anticorps permet aux ADCs de cibler des r\u00e9cepteurs tr\u00e8s sp\u00e9cifiques exprim\u00e9s par une cellule canc\u00e9reuse. Ces traitements peuvent donc d\u00e9livrer la mol\u00e9cule cytotoxique dans les cellules des tumeurs, sans affecter les cellules saines.<\/p>\n

Depuis 2006, Lonza<\/a> s’est aventur\u00e9e sur le march\u00e9 des traitements bioconjugu\u00e9s, dont font partie les ADCs. Elle dispose d\u00e9j\u00e0 de capacit\u00e9s de production pour les anticorps adapt\u00e9s aux antig\u00e8nes cibl\u00e9s, les charges utiles et les liants de ces deux \u00e9l\u00e9ments sur ses sites \u00e0 Visp (canton du Valais) et au Royaume-Uni. En acqu\u00e9rant Synaffix<\/a>, Lonza prend le contr\u00f4le d’une plateforme technologique pour le d\u00e9veloppement de ces traitements en phase clinique, \u00e9largissant ainsi son offre en amont de la production. Les activit\u00e9s de Synaffix seront maintenues sur son site \u00e0 Oss, aux Pays-Bas.<\/p>\n

Selon une estimation publi\u00e9e en mai, relay\u00e9e par Lonza, le march\u00e9 des ADC devrait d\u00e9passer USD 22 milliards d’ici \u00e0 2030. En Suisse, le secteur des ADC a connu une activit\u00e9 significative. En 2013, Roche a lanc\u00e9 l’un des premiers traitements de ce genre, Kadcyla, destin\u00e9 \u00e0 combattre une forme agressive de cancer du sein. En 2022, ce m\u00e9dicament a g\u00e9n\u00e9r\u00e9 CHF 2,1 milliards de CHF pour le laboratoire bas\u00e9 \u00e0 B\u00e2le, qui dispose maintenant d’autres traitements similaires.<\/p>\n","protected":false},"excerpt":{"rendered":"

Le g\u00e9ant pharmaceutique Lonza renforce ses capacit\u00e9s dans le d\u00e9veloppement de nouveaux traitements contre le cancer avec \u00e0 un investissement de plus de CHF 97 millions \u00e0 Vi\u00e8ge.<\/p>\n","protected":false},"author":3,"featured_media":11906,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1022,1054,1058,1065,1069],"class_list":["post-11905","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr","tag-investment-fr","tag-manufacturing-fr","tag-oncology-fr","tag-pharma-fr"],"acf":[],"yoast_head":"\nLonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"Le g\u00e9ant pharmaceutique Lonza renforce ses capacit\u00e9s dans le d\u00e9veloppement de nouveaux traitements contre le cancer avec \u00e0 un investissement de plus de CHF 97 millions \u00e0 Vi\u00e8ge.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-07T03:08:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:44:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux\",\"datePublished\":\"2023-06-07T03:08:14+00:00\",\"dateModified\":\"2023-07-04T11:44:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/\"},\"wordCount\":366,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg\",\"keywords\":[\"Biotech\",\"Investment\",\"Manufacturing\",\"Oncology\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/\",\"name\":\"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg\",\"datePublished\":\"2023-06-07T03:08:14+00:00\",\"dateModified\":\"2023-07-04T11:44:20+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg\",\"width\":640,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/","og_locale":"fr_FR","og_type":"article","og_title":"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux - Greater Geneva Bern area","og_description":"Le g\u00e9ant pharmaceutique Lonza renforce ses capacit\u00e9s dans le d\u00e9veloppement de nouveaux traitements contre le cancer avec \u00e0 un investissement de plus de CHF 97 millions \u00e0 Vi\u00e8ge.","og_url":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-06-07T03:08:14+00:00","article_modified_time":"2023-07-04T11:44:20+00:00","og_image":[{"width":640,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"mathieu","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux","datePublished":"2023-06-07T03:08:14+00:00","dateModified":"2023-07-04T11:44:20+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/"},"wordCount":366,"image":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg","keywords":["Biotech","Investment","Manufacturing","Oncology","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/","url":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/","name":"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg","datePublished":"2023-06-07T03:08:14+00:00","dateModified":"2023-07-04T11:44:20+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Lonza-Ibex-Visp-630x380-1-4.jpg","width":640,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/lonza-investit-chf-97-millions-a-viege-pour-sa-nouvelle-generation-danticancereux\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Lonza investit CHF 97 millions \u00e0 Vi\u00e8ge pour sa nouvelle g\u00e9n\u00e9ration d\u2019anticanc\u00e9reux"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=11905"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11905\/revisions"}],"predecessor-version":[{"id":18384,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11905\/revisions\/18384"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/11906"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=11905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=11905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=11905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}